Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab tapering and interruption in GCA
NCT03244709Phase 4Unknown
- Sponsor
- Santo Stefano Riabilitazione
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in giant cell arteritis (GCA), sponsored by Santo Stefano Riabilitazione. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03244709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244709.